Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Abstract Background Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels ≥50% [1]. However, it is not effective in all patients, and the factors predicting responses among this popula...

Full description

Bibliographic Details
Main Authors: Mitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, Akihiro Tamiya, Hidekazu Suzuki, Katsuya Hirano, Yasushi Fukuda, Toshihide Yokoyama, Ryota Kominami, Masaki Kanazu, Junji Uchida, Satoshi Hara, Shuji Yamashita, Hiromi Tomioka
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Pembrolizumab
First-line therapy
Efficacy
Programmed death ligand-1
Online Access:https://doi.org/10.1186/s12885-020-6582-4

Internet

https://doi.org/10.1186/s12885-020-6582-4

Similar Items